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Abstract — Aims: To investigate the relationship between the sweet liking/sweet disliking phenotype (a putative probe of brain
opioid function), craving for alcohol and response to treatment with naltrexone in individuals with alcohol dependence. Methods:
Forty individuals with alcohol dependence were enrolled in a 12-week open-label study of 50 mg of naltrexone with four sessions of
motivational enhancement therapy. Prior to treatment, individuals completed a sweet preference test and the Penn Alcohol Craving
Scale. Subjects were categorized as sweet liking (SL), n = 15, or sweet disliking (SDL), n = 25, via a standard sweet tasting paradigm.
The sweet tasting results were blinded to the subjects and to treatment staff. SL status, pretreatment craving and their interaction
were examined as predictors of frequency of abstinent days and heavy drinking days during treatment with naltrexone. Results: SL
and SDL subjects achieved similar reductions in percent heavy drinking days with treatment. During treatment, SDL subjects had
48% abstinent days compared to 30% for SL subjects (P = 0.034). Pretreatment craving did not predict % heavy drinking days or %
abstinent days. An interaction effect was found between the SL/SDL phenotype and pretreatment craving such that SL subjects with
high craving demonstrated higher rates of percent abstinent days whereas SDL subjects with high craving demonstrated lower rates of
percent abstinent days, P < 0.001. Conclusions: These findings indicate that the SL/SDL phenotype may predict variation in response
to naltrexone and/or counseling treatment. Furthermore, the SL/SDL phenotype may interact with craving to provide a more robust
prediction of outcome with naltrexone or counseling.
INTRODUCTION
Naltrexone was the first approved medication in the United
States to address the central nervous system actions of alcohol.
Its efficacy has now been investigated in around 3000 alcohol-
dependent subjects in randomized, placebo-controlled, single-
center and multicenter trials. Meta-analyses of these studies
support the initial finding that naltrexone is modestly effective
in reducing relapse to heavy drinking and reducing drinking
frequency and less effective in enhancing abstinence (Kranzler
and Van Kirk, 2001; Streeton and Whelan, 2001; Srisurapanont
and Jarusuraisin, 2002; Bouza et al., 2004). Whereas the overall
effect of naltrexone may be modest, for some individual patients
the effect appears to be strong. Therefore, one of the challenges
with using naltrexone in the clinical setting is assessing and
then predicting which patients are likely to experience a good
response to naltrexone.
To date, there has been limited information to help the clin-
ician decide which patient should receive a trial of naltrexone.
Several factors have been tentatively identified in the literature
as positively associated with naltrexone response—high base-
line craving for alcohol (Monterosso et al., 2001; Volpicelli
et al., 1995; Jaffe et al., 1996, not confirmed by Keifer et al.,
2005); increased density of familial alcohol problems
(Monterosso et al., 2001; Rubio et al., 2005; Rohsenow et al.,
2007; Tidey et al., 2008); early onset of alcohol problems
(Rubio et al., 2005) and the A118G variant polymorphism in the
µ-opioid receptor (Oslin et al., 2003; Anton et al., 2008; not
confirmed by Gelernter et al., 2007). Many of these markers
are associated with functional activity of the endogenous opioid
system. For example, the 118G allele of the µ-opioid receptor
gene (OPRM1) has been associated with stronger binding of
β-endorphin to the µ-opioid receptor (Bond et al., 1998), a
positive family history of alcoholism has been reported to be
associated with low baseline β-endorphin levels in the brain
(Gianoulakis et al., 1989) and severity of alcohol craving has
been shown to be linked to availability (Heinz et al., 2005)
and binding potential (Bencherif et al., 2004) of postsynaptic
µ-opiate receptors. These findings indicate that predictors of
naltrexone response may be identified through assessment of
the functional activity of the endogenous opioid system.
A growing body of evidence indicates that the hedonic re-
sponse to sweet taste reflects activity of the endogenous opioid
system (Calcagnetti and Reid, 1983; Leventhal et al., 1995;
Pecina and Berridge, 2005). The hedonic response to sweet
taste is a stable and heritable trait (Mennella et al., 2005;
Keskitalo et al., 2007), associated with genetic risk of exces-
sive alcohol intake in animals (for review, see Kampov-Polevoy
et al., 1999) and genetic risk of alcohol dependence (AD) in
humans (Kampov-Polevoy et al., 2001, 2003a, 2003b; Pepino
and Mennella, 2007; Wronski et al., 2007). In humans, hedonic
response to sweet taste generally yields two broad types—SL
and SDL (Thompson et al., 1976; Looy et al., 1992). SL indi-
viduals note increasing pleasantness of sucrose concentrations
up to 2.0 M whereas SDL do not like sucrose concentrations
above the 0.4 M range.
We know of no study that has compared outcomes from
treatment according to sweet liking.
We hypothesize that hedonic response to sweet taste, as a
phenotypic probe of the endogenous opioid system, may be
useful to predict naltrexone response in patients with AD. To
test this hypothesis we conducted an open-label trial of naltrex-
one in AD subjects using the SL/SDL phenotype as a blinded
predictor of drinking during treatment. We also examined the
effects of the SL/SDL phenotype on (1) the ability to achieve
abstinence prior to treatment with naltrexone, i.e. during the
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Table 1. Baseline Demographics of SL and SDL Subgroups
SL/SDL subgroups
Total sample
(n = 40) SDL (n = 25) SL (n = 15)
Age 49 ± 9 48 ± 9 51 ± 7
Males (%) 73% 64% 86%
Married (%) 68% 64% 73%
Baseline % heavy drinking
days (%HDD)
76% 76% ± 23% 75% ± 26%
Baseline % abstinent days
(%ABST)
11% 12% ± 16% 10% ± 17%
PACS 14.6 ± 5.5 14.4 ± 4.4 14.8 ± 7.2
Years alcohol dependent 14 ± 11 12 ± 9 17 ± 14
Abstinence as goal of
treatment
27% 32% 20%
period between eligibility assessment and randomization, and
(2) the interaction between the SL/SDL phenotype and initial




The study sample consisted of 40 AD subjects, who met
inclusion/exclusion criteria and received at least one dose of
naltrexone (for demographic characteristics, see Table 1).
Screening and eligibility criteria
The study was conducted at the University of North Carolina,
Chapel Hill, between November 2003 and January 2005. Sub-
jects were recruited from newspaper and radio advertisements
targeted to individuals who wished to change their drinking
behavior. The protocol was approved by the Committee on
the Protection of the Rights of Human Subjects, School of
Medicine, University of North Carolina at Chapel Hill.
Men and nonpregnant women aged 21 years and older with
AD were eligible. Potential subjects were initially screened on
the telephone and those who appeared to meet broad study cri-
teria and were interested in participation were scheduled for
a screening visit (week −1). At the screening visit, subjects
signed informed consent and received a breath alcohol test that
had to be 0.0 g/dl in order to proceed with the screening visit.
Subjects were then given a medical examination and medical
history interview, were asked about prescription and over-the-
counter medication use, and had blood drawn for aspartate
aminotransferase (AST), alanine aminotransferase (ALT), γ -
glutamyltransferase (GGT), bilirubin, alkaline phosphatase and
a serum pregnancy test. A urine toxicology screen was com-
pleted. Individuals also completed a 90-day timeline follow-
back interview (TLFB; Sobell et al., 1988) and the Penn Alchol
Craving Scale (PACS) (Flannery et al., 1999). Trained inter-
viewers administered the Mini International Neuropsychiatric
Interview (MINI; Sheehan et al., 1999) to determine psychiatric
diagnoses.Subjects were required to meet DSM-IV criteria for
AD and to have at least two episodes of heavy drinking (defined
as four standard alcohol drinks/day for women and five standard
alcohol drinks/day for men) per week during the 30 days prior
to screening. The subjects were excluded if they had a history in
the past year of drug dependence other than nicotine or alcohol
or if they had a positive urine toxicology test at screening. Sub-
jects who had a positive urine cannabinoid test were allowed in
the study if there was no evidence for cannabinoid dependence.
Exclusion criteria included (1) clinically significant medical
illness; (2) significant psychiatric disorder including depres-
sion with suicidal ideation, bipolar disorder or schizophrenia;
(3) current use of psychotropic medication, including medica-
tion for alcohol dependence, with the exception of a stable dose
for ≥ 8 weeks of a selective serotonin reuptake inhibitor (SSRI)
and (4) elevated bilirubin, documented cirrhosis or an ALT or
AST level >2.5× upper limit of normal.
Overall, 54 subjects were screened to yield 40 subjects who
met inclusion/exclusion criteria and received at least one dose
of naltrexone. Screen failures occurred for the following rea-
sons: five patients had comorbid psychiatric illness, four had
inadequate level of alcohol consumption, three withdrew con-
sent, one did not reach DSM-IV criteria for AD and one had
elevated liver enzymes. All subjects signed written informed
consent.
Overall study design. The study was a 12-week, open-label
trial of naltrexone. Following the screening visit, individuals
were asked to achieve 3 days of sobriety before starting nal-
trexone. The length of time it took for individuals to achieve
3 days of sobriety varied; thus the time between screening and
naltrexone initiation varied from one to several weeks. Though
the trial was designed as a 12-week study, some individuals
were followed for longer than 12 weeks before study termina-
tion because of missed visits and scheduling logistics.
Study procedures
At the initial treatment visit (week 0) and all subsequent study
visits (weeks 1, 2, 3, 4, 6, 8, 10 and 12), a breath alcohol test
was administered, and vital signs were recorded. The Clinical
Institute for Alcohol Withdrawal scale, Revised (Sullivan et al.,
1989), was administered to assess for symptoms of significant
alcohol withdrawal. No one required referral for medication
detoxification. Naltrexone dosing was titrated from 25 mg/day
for the first 3 days to 50 mg/day for the remainder of treatment.
Naltrexone blister packs were distributed four times during
treatment: at weeks 0, 1, 4 and 8. Additionally, calendars were
provided so that participants could record the number of pills
taken, the number of drinks consumed and any side effects
experienced. At each visit, subjects were asked about use of
concomitant medications and completed the TLFB and PACS.
At week 4, blood was drawn to assess AST, ALT, GGT and
bilirubin values. At week 12, or early termination, a complete
physical was conducted, and AST, ALT, GGT, bilirubin and
alkaline phosphatase levels measured. Pregnancy testing was
conducted each month for female participants of childbearing
potential.
The first of four Motivational Enhancement Treatment
(MET) sessions was conducted on day 0. Additional MET ses-
sions were provided at weeks 1, 6 and 12. Counselors who
were trained following MET manual guidelines published by
NIAAA (NIH, 1994) provided MET therapy. Counseling in-
cluded having each participant state his/her goal for treatment
(i.e. abstinence, reduction in drinking) and encouragement
to work toward his/her stated goal. Counselors did not push
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subjects for abstinence though this goal was discussed and en-
couraged as appropriate.
Sweet taste test methodology
At the initial study visit, participants’ sensitivity and hedonic
response to sweet taste were tested using our standard method-
ology (Kampov-Polevoy et al., 2003b). Testing was conducted
prior to taking naltrexone and after 3 days of abstinence from
alcohol. Prior to testing, participants fasted for 2 h and abstained
from smoking for 1 h. Each subject was instructed to sip, swish
around his/her mouth and then spit out five different concen-
trations of a sweet solution (0.05, 0.10, 0.21, 0.42 and 0.83 M)
each of which were presented five times in a pseudorandom
order for a total of 25 tastings. After each tasting, participants
rinsed their mouths with distilled water before proceeding to
the next solution. The participants then rated the intensity and
pleasureableness of each tasting using a 200 mm analog scale.
The Sweet Taste Test was conducted by a research assistant
who was not involved in any other assessments. The subject
and those staff involved in assessing and managing the subject
were kept blind to the Sweet Taste Test results until the entire
study was completed.
Determination of sweet liking status. Subjects were assigned
to one of two categories—SL or SDL—based upon their he-
donic response to the various sucrose concentrations. To be
categorized as a sweet liker, a subject must have rated the high-
est concentration of sucrose (0.83 M) as the most pleasurable.
Sweet-dislikers could prefer any of the other four concentra-
tions (Kampov-Polevoy et al., 1997). Such categorization has
been shown to be stable over time. For example, our previous
study indicated a high correlation (r = 0.72; P < 0.0001) be-
tween the results of two sweet tests conducted in patients at
admission and before discharge from a residential treatment
program for substance use disorders (Kampov-Polevoy et al.,
2003b).
Outcome measures
The primary drinking outcome measure was percent heavy
drinking days. Secondary outcome measures included study
retention, time to first heavy drinking day and to 2 consecutive
heavy drinking days, percentage days abstinent, time to first day
abstinent and time to 2 consecutive abstinent days and craving
for alcohol prior to and during treatment. In addition, we noted
how long it took for a patient to achieve 3 consecutive days
of abstinence prior to the beginning of naltrexone treatment.
Tolerability was assessed by records of side effects, dropouts
due to side effects, laboratory values and serious adverse
events.
Statistical analysis
All values are given as the mean ± standard deviation (SD)
or, for model-based estimates, the values are given as the es-
timate followed by the standard error (SE) and this is noted.
Model-based estimates allow for adjustments for predictors,
covariates and complex designs such as repeated measures.
Baseline drinking was defined as drinking during the period
of time that included the 90-day period prior to the screening
visit plus the period between the screening and initial study
visits minus the mandatory 3 days of abstinence. The average
duration of this period was 102 ± 5 days. Baseline differences
in demographic variables and level of baseline drinking were
investigated using independent sample t-tests for continuous
variables and chi-square tests of independence for categorical
variables. In the presence of small or empty cells in the tests
of categorical variables, the chi-square test was replaced by
Fisher’s exact test.
For simple cross-sectional comparisons (e.g. comparison be-
tween groups at one point in time), independent sample t-tests
were used for continuous outcome variables. In the presence of
covariates, independent sample t-test was replaced by analysis
of covariance (ANCOVA). The data provided weekly scores
of abstinence and heavy drinking for each subject during the
12 weeks of medication.
For comparison between groups at one point in time, in-
dependent sample t-tests were used for continuous outcome
variables. In the presence of covariates, independent sample
t-tests were replaced by ANCOVA model. With the available
data, we produced weekly scores of abstinence and heavy
drinking for each subject during the 12 or more weeks of
the medication period. With this sample, we implemented a
general mixed-model analysis of variance (MMANOVA) to
accommodate the within subject correlation present with the re-
peated measures (Schwarz, 1993). This framework models the
means per group over the respective time period (i.e. weeks) and
the covariance between the repeated measures over the assess-
ments, and has been implemented in substance abuse research
(Greenfield et al., 2007). For this sample, the MMANOVA
approach estimates the on-average difference over the medi-
cation period between groups (sweet liking versus sweet dis-
liking). To answer this difference between groups, a group
main effect is modeled in the MMANOVA. The MMANOVA
was implemented with SAS procedure PROC MIXED
(Littell et al., 2006).
For the time to events outcomes, we implemented survival
curves, which were estimated using the Cox proportional haz-
ards model. As is typically done, patients lost to follow-up
were treated as censored observations, as were patients who
never achieved the event of interest. Survival models were im-
plemented in SAS with the procedure PROC PHREG (Allison,
1997).
MMANOVA and Cox proportional hazards models allow for
additional predictors or covariates to be included in all anal-
yses. Specifically, one predictor of interest was the baseline
craving. Our interest was in assessing the relationship between
craving prior to treatment and its impact on abstinence and
heavy alcohol use. For all analytical models, we included crav-
ing in the analysis to determine if it had an association with
alcohol usage, or its association with alcohol usage was differ-
ent across sweet liking classification. Determination of craving
as a predictor of usage dependent on sweet liking status was in-
spected through including the interaction of craving with sweet
liking status in the statistical model. A significant interaction
would indicate the differential impact of craving on outcome as
a function of sweet liking classification. If the interaction was
non-significant, the interaction was removed from the statisti-
cal model. A significant main effect for craving would indicate
craving as predictive of usage and that this prediction did not
depend on the sweet liking status.
All analyses were conducted using SAS Version 9.1.3. Sta-
tistical significance was set at P < 0.05 (two-tailed) for all tests,
unless specified otherwise.
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RESULTS
Demographics, sweet liking status, craving for alcohol and
alcohol use history
Fifteen subjects were categorized as SLs and 25 as SDLs. Par-
ticipants included 29 men and 11 women and 97.5% of the
subjects were Caucasian. As shown in Table 1, there were no
differences between SL and SDL subjects in demographic data
(age, gender, marital status) and in drinking variables. Base-
line PACS scores were similar between SL and SDL subjects.
Fewer SL subjects identified abstinence as a goal of treatment
but this was not statistically significant. The baseline levels of
AST, ALT and bilirubin were within the protocol limits and
remained within limits during treatment.
Retentions rates and tolerability
There were no differences in retention rates between groups:
82% of SL and 76% of SDL subjects completed the study.
No differences in tolerability were noted between SL and SDL
subjects.
Pre-naltrexone findings
All patients achieved the 3 abstinence days prior to the onset
of medication; therefore, no censoring was present. SL patients
took ∼40% longer (14.1 ± 6.0 days) to achieve the required
3 abstinent days before medication compared to SDL patients
(10.1 ± 4.3 days; P = 0.02).
Naltrexone findings
Percent heavy drinking days. Both SL and SDLs demon-
strated a sharp reduction in the percent heavy drinking days
from pre-treatment to the active medication period from 75%
± 25.6% to 17% ± 28.8% for SL and from 76% ± 23.3%
to 20% ± 24.6% for SDL. Overall, we found a significant re-
duction in heavy usage from the pre-treatment period to the
medication period as assessed through a paired t-test [t(39) =
12.35, P < 0.0001]. The MMANOVA estimated proportion of
heavy usage during the medication period was 0.190 (SE =
0.042) for SDL subjects and 0.128 (SE = 0.049) for SL sub-
jects, with an estimated mean difference of 0.062 (SE = 0.056)
that was not significant. To assess if this estimated difference
between SL and SDL groups was consistent across the 12-week
medication period, we included an interaction of the SL sta-
tus indicator and week to the MMANOVA—no evidence of a
group by time interaction was found.
Cox regression analysis indicated no significant difference
between SLs (median = 10 ± 2.6 days with 33.3% survival)
and SDLs (median time = 6 ± 1.1 days, with 34.6% survival)
in time to first heavy drinking day or time to 2 consecutive
drinking days’ SLs (median = 58 ± 6.9 days with 45.0%
survival) and SDLs (median = 40 ± 6.5 days, with 39.9%
survival).
Percent days abstinent. Both SL and SDLs demonstrated a
sharp increase in the percent of abstinence from pre-treatment
to the active medication period. Abstinence increased from
10% ± 17.3% to 29% ± 35.8% for SL and from 12% ± 15.9%
to 48% ± 33.9% for SDL. Overall, we found a significant
increase in abstinence from the pre-treatment period to the
medication period as assessed through a paired t-test [t(39) =
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Fig. 2. Within-treatment time to 2 consecutive abstinent days by SL/SDL
phenotype, Chi(1) = 6.88, P = 0.009.
the medication period varied across SL status we implemented
the MMANOVA model, while controlling for the pre-treatment
abstinence. The MMANOVA estimated a proportion of absti-
nence of 0.483 (SE = 0.055) for SDL subjects and 0.300 (SE
= 0.068) for SL subjects, with a estimated mean difference of
0.183 (SE = 0.083), [F(1,37) = 4.84, P < 0.04]. Examination
of change in abstinence over time by the SL/SDL group did not
reveal any group differences, i.e. the differences in abstinent
days persisted over the entire naltrexone treatment period, see
Fig. 1.
Cox regression analysis indicated no significant difference
between SDLs (median = 2 ± 2.5 days, with 14.0% survival)
and SLs (median = 1 ± 2.0 days, with 0% survival) in time to
first drinking day. However, SL subjects were much less likely
than SDL subjects to achieve 2 consecutive abstinent days, Cox
regression difference between SDLs (median time = 4 ± 5.4
days, with 94.0% survival) and SLs (median = 44 ± 9.2 days
with 63.4% survival) [chi(1) = 6.88, P < 0.01; Fig. 2].
Association between pill compliance and SL status
Independent sample t-test per assessment of compliance of
medication indicated no significant difference between SDL
and SL groups. At the first assessment a proportion of com-
pliance of 0.92 ± 0.21 for SDL and of 0.93 ± 0.23 for SL
was found. Similarly, at the last assessment of compliance, a
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Fig. 3. Association between initial alcohol craving (PACS-T0) and treatment outcome (percent abstinent days) in SL and SDL patients.
proportion of compliance of 0.98 ± 0.05 for SDL and of 0.99
± 0.01 for SL was found.
Association between alcohol craving as measured by PACS
during the screening visit (PACS-T0) and outcome with nal-
trexone
We tested the hypothesis suggested by Monterosso et al. (2001)
that severity of alcohol craving measured prior to treatment
can predict outcome with naltrexone. A sequential regression
analysis using the proportion of heavy usage and proportion
of abstinence during the entire medication period showed that
initial alcohol craving as measured by PACS-T0 does not predict
treatment outcome either in terms of percent heavy drinking
days or percent abstinent days.
We then tested whether the association between initial al-
cohol craving and treatment outcome depended on the SL and
SDL grouping by including the interaction between the craving
status and SL/SDL grouping. We found a significant interaction
between craving and SL/SDL grouping for percent abstinent
days [F(1,36) = 8.84, P < 0.01] but a non-significant inter-
action for percent heavy drinking days. To further understand
this relationship, we implemented the mixed-effects modeling
framework on our 12 weeks of usage measures including the
SL/SDL status and baseline craving in the model. The anal-
ysis showed a significant interaction between PACS-T0 and
SL/SDL status in the prediction of percent abstinent days (but
not percent heavy drinking days) [F(1,36) = 13.94, P < 0.001]
(Fig. 3) indicating that differences between SL/SDL status on
the likelihood of achieving abstinence interacted with initial al-
cohol craving score, see Fig. 3a and b. Extending this repeated
measures analysis we found a non-significant three-way inter-
action of PACS-T0, SL/SDL status and week, indicating that the
differential relationship of craving with abstinence per group
(SL versus SDL) is consistent across the 12-week medication
period. In the SL group, a positive correlation between PACS-
T0 and percent abstinent days was present indicating that SL
subjects with higher craving had more abstinent days when
treated with naltrexone. In SDL subjects, the correlation was
negative indicating that in SDL subjects higher craving was
associated with less abstinence.
DISCUSSION
Naltrexone, an antagonist at µ, δ and κ-opioid receptors, is
thought to block alcohol-induced opioid activation of reward
pathways thereby counteracting aspects of the positive response
to alcohol. Subjects in clinical trials who receive naltrexone,
overall, report diminished feelings of being ‘high’ after con-
suming alcohol (Volpicelli et al., 1995; O’Malley et al., 1996),
note less craving for alcohol (Volpicelli et al., 1992; O’Malley
et al., 1996), are less likely to relapse to heavy drinking
(Kranzler and Van Kirk, 2001; Srisurapanont and Jarusuraisin,
2002) and achieve greater rates of abstinence (Kranzler and Van
Kirk, 2001). However, for groups of patients, these actions are
modest with mean effect sizes in the 0.1–0.2 range (Kranzler
and Van Kirk, 2001) that has contributed to the low utilization
of naltrexone in clinical practice (Mark et al., 2003).
Efforts to identify which patients respond to naltrexone
have utilized two principal approaches—examination of clin-
ical phenomenology and examination of biogenetic markers,
(see the Introduction section). These predictors are not clearly
established and, indeed, some have not been confirmed, e.g.
Kiefer et al. (2005), failed to find an association between crav-
ing and naltrexone response. Nevertheless, these efforts suggest
that predictors of naltrexone response can be identified and, if
confirmed and refined, might have practical clinical value.
Variation in the brain’s opioid system is an obvious tar-
get to identify naltrexone predictors. The hedonic response to
sweet taste represents a heritable trait (Keskitalo et al., 2007)
that likely provides information on brain opioid activity (see
Pecina and Berridge, 2005). The results of the present study
indicate that variation in the hedonic response to sweet taste is
associated with the ability to achieve and maintain abstinence
prior to treatment as well as during naltrexone treatment plus
counseling.
Prior to initiating treatment, SL patients required a longer
time to achieve 3 consecutive days of abstinence before start-
ing naltrexone compared to SDL patients. This suggests that
the propensity to drink alcohol may be stronger in SL subjects
such that they have greater difficulty in achieving periods of
abstinence. The biological underpinnings of this finding are not
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clear but could relate to altered opioid function in SL individ-
uals (see below).
All patients demonstrated a sharp reduction in the percent-
age of heavy drinking days during the treatment period—from
∼75% to ∼20%, regardless of their SL/SDL status. The robust
effect of this treatment is consistent with results reported in
other published clinical trials, e.g. Garbutt et al., (2005).
However, SL and SDL individuals differed significantly in
their ability to abstain from alcohol (see Fig. 1). The median
time to achieve 2 consecutive abstinent days for SL patients
was 10 times longer than for SDL patients (Fig. 2). In other
words, for SL patients achieving and maintaining sobriety dur-
ing treatment was considerably more difficult than for SDL
patients—consistent with our finding that SL patients took
longer to achieve sobriety prior to starting naltrexone.
The other major post-treatment difference between SL and
SDL patients was in the relationship between baseline crav-
ing for alcohol and the likelihood of achieving abstinent days.
Several groups have reported that the level of severity of
the baseline craving for alcohol positively correlates with re-
sponse to naltrexone (Volpicelli et al., 1995; Jaffe et al., 1996;
Monterosso et al., 2001). In our trial we failed to find such
an association in the whole sample though in the absence of a
placebo-control we were unable to test for a relationship be-
tween craving and naltrexone effect size as Monterosso et al.
(2001) did. However, when the SL/SDL phenotype was in-
cluded in the analysis a highly significant interaction effect
between craving, SL/SDL phenotype and percent abstinent
days emerged. SL patients demonstrated a positive correla-
tion between PACS-T0 and percent abstinent days, indicating
that those with higher craving had more abstinent days when
treated with naltrexone as suggested in the literature. On the
other hand, SDL subjects showed a negative correlation indicat-
ing that, for SDL subjects, higher craving is associated with less
abstinence.
The reason why the combination of the SL/SDL pheno-
type and craving improves predictive power is not clear.
However, one hypothesis is that hedonic response to sweet
taste and alcohol craving probe different components of the
brain opioid system such that taken together they are more
informative than taken separately. Whereas no direct stud-
ies in humans have yet been conducted to investigate the
relationship of the SL/SDL phenotype to endogenous opi-
oid function, there is extensive animal evidence demonstrat-
ing the critical role opioids play in mediating the hedo-
nic response to sweets (see Pecina and Berridge, 2005).
Furthermore, given the evidence that the SL phenotype is as-
sociated with familial risk for alcoholism, it could be hypoth-
esized that SL is associated with an inherent dysfunction of
β-endorphin release from presynaptic terminals as reported in
individuals at high risk for alcoholism (Gianoulakis, 2004).
Conversely, craving for alcohol has been linked to the avail-
ability (Heinz et al., 2005) and binding potential (Bencherif
et al., 2004) of postsynaptic µ-opiate receptors. Therefore, a
combination of the SL/SDL phenotype and craving may pro-
vide a more integrative measure of brain opioid function.
Another question is why the combination of hedonic re-
sponse to sweet taste and initial alcohol craving had a pre-
dictive value regarding percent abstinent days but not per-
cent heavy drinking days. One potential explanation of this
phenomenon is that the overall treatment effect of counsel-
ing and naltrexone caused robust suppression of percent heavy
drinking days in both SL and SDL groups but for different
reasons—SL individuals responded to naltrexone while SDL
individuals responded to counseling. Another potential expla-
nation of this outcome is that loss of control over drinking
within a drinking episode and inability to abstain from drink-
ing may be determined by different opioidergic mechanisms
that have different sensitivity to naltrexone treatment. For ex-
ample, heavy drinking is often attributed to elevated sensitivity
to the rewarding effect of alcohol stemming from increased
β-endorphin release from presynaptic terminals in response to
ethanol (Gianoulakis, 2004). Naltrexone treatment by reducing
the pleasure or the ‘high’ associated with alcohol intake (King
et al., 1997, 2002) may reduce alcohol consumption during a
drinking episode.On the other hand, the effect of naltrexone
treatment on the ability to abstain from alcohol may be related
to its effect on alcohol craving that is associated with the avail-
ability (Heinz et al., 2005) and binding potential (Bencherif
et al., 2004) of postsynaptic µ-opiate receptors. However, at
this point these conclusions are still highly speculative.
Study limitations
The sample size of the study is modest at 15 SL and 25 SDL
subjects. This could lead to a type 1 error though some of the
statistical findings, e.g. the interaction effect between craving
and SL/SDL status, revealed very robust results, which leads to
greater confidence in the finding. With the limited sample size
and the preliminary nature of this research, we did not adjust
the alpha-level for any statistical contrast (Rothman, 1990).
This lack of adjustment could lead to an inflated type I error
as well. Another important limitation is the lack of a placebo
group. Without a placebo group the effects of naltrexone versus
counseling in SL versus SDL patients cannot be disentangled.
This is particularly problematic for the interpretation of the
heavy drinking results where both SL and SDL patients showed
similar outcomes. As noted earlier, this result could be because
both groups respond equally well to naltrexone or it could be,
as we hypothesize, that SL patients show a superior response to
naltrexone compared to placebo whereas SDL patients respond
primarily to counseling.
In summary, we have found preliminary evidence that the
SL phenotype predicts fewer days of abstinence in alcohol-
dependent patients who are treated with naltrexone and coun-
seling. Furthermore, we also found that the SL/SDL phenotype
interacts with craving for alcohol such that SL patients who
have high levels of craving are more likely to achieve absti-
nence whereas SDL patients with high levels of craving are
less likely to achieve abstinence. These findings require con-
firmation and extension but support the hypothesis that the SL
phenotype may be useful in advancing understanding of the
biological heterogeneity of alcohol dependence and its rela-
tionship to naltrexone and treatment response.
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